Evonik Industries Boston Consulting Group Matrix
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Evonik Industries Bundle
See the Bigger Picture
Evonik’s BCG Matrix paints a quick, honest picture of where its product lines sit — the Stars driving growth, the Cash Cows funding R&D, and the Question Marks that need decisions. This preview hints at strategy; the full BCG Matrix gives quadrant-level placements, actionable recommendations, and ready-to-use Word and Excel files. Buy the complete report to skip the guesswork and start reallocating capital with confidence.
Stars
High‑performance polymers (PA12 & 3D printing)
Evonik’s PA12 and adjacent high‑performance polymers sit squarely in fast‑growing 3D printing and e‑mobility niches, with PA12 widely specified for SLS and functional EV components, driving strong share and low churn via specification lock‑in. Applications are scaling but still need heavy application development and go‑to‑market support to reach commercial run rates. Continued investment can compound into a dominant, cash‑rich platform.
Silica for EV/green tires
Silica solutions that cut rolling resistance ride the EV and sustainability surge, with EVs accounting for about 14% of global passenger car sales in 2024 (IEA). Evonik’s advanced silica tech and strong customer stickiness translate into a high share in the growing green-tire segment and close OEM partnerships. It soaks up capex and technical service to meet OEM specs but is worth the spend, retaining leader status and expanding as EV mix rises.
Specialty additives for lightweight composites & battery systems
Additives that enable lighter, tougher composite parts and safer Li-ion batteries are high-growth winners in new vehicle and energy platforms; Evonik reported double-digit growth in specialty additives in 2024, reflecting strong OEM demand. Customers prioritize performance over price, supporting premium-margin positions. Long sales cycles mean technical selling and pilot lines are decisive. Invest now to cement positions before standards and supplier lists harden.
Premium personal care actives & delivery systems
Skin and hair brands keep trading up to performance actives and clean-label systems, with the global active ingredients market rising about 5% in 2024 and innovation-led premium segments outperforming mass categories. Evonik carries credibility and breadth across actives and delivery systems, with sticky formulations driving repeat wins and strong account retention. Keep launching hero ingredients and back key accounts hard to defend share and margin.
- Market growth ~5% (2024)
- Evonik: broad active/delivery portfolio
- Sticky formulations = repeat sales
- Strategy: launch heroes + support key accounts
Biotech‑enabled animal nutrition solutions
Biotech‑enabled animal nutrition is a Star: higher‑efficiency, lower‑footprint feed solutions scale with protein demand and tightening regulation; the global feed additives market was about USD 34.2bn in 2024 with a ~4.6% CAGR to 2030, and Evonik's animal nutrition exceeded €1.3bn in sales (2023), showing meaningful share as the category expands. Differentiation is know‑how and data, not tonnage; double down on trials, digital advisory and quantified sustainability proof points to protect growth.
- Market: USD 34.2bn (2024), CAGR ~4.6% to 2030
- Evonik: animal nutrition >€1.3bn sales (2023)
- Value driver: data/know‑how > commodity tonnage
- Actions: scale trials, digital advisory, measurable sustainability KPIs
Specialty tailwinds: double‑digit additives growth, EVs ~14% of sales, animal nutrition >€1.3bn
Evonik’s Stars—PA12/high‑performance polymers, advanced silica, specialty additives, premium skin actives and biotech animal nutrition—hold high share in fast‑growing niches (3D printing, EVs, green tires, premium care, feed). 2024 signals: double‑digit specialty additives growth, animal nutrition >€1.3bn (2023), EVs ~14% of car sales (IEA 2024). Continued capex and technical selling needed to scale to cash generation.
| Segment | 2024 data | Evonik metric | Notes |
|---|---|---|---|
| PA12 / polymers | 3D/EV niches growing fast | High share, spec lock‑in | Needs application dev |
| Silica (green tires) | EVs ~14% global sales (IEA 2024) | Leader in low‑RR silica | OEM specs → capex |
| Additives | Double‑digit growth (2024) | Premium margins | Long technical sales |
| Skin actives | Market ~+5% (2024) | Broad portfolio | Sticky formulations |
| Animal nutrition | Market USD 34.2bn (2024) | >€1.3bn sales (2023) | Scale trials, data |
What is included in the product
Detailed Word Document
In-depth BCG Matrix review of Evonik's units, detailing Stars, Cash Cows, Question Marks, Dogs with investment and divestment guidance.
Customizable Excel Spreadsheet
One-page Evonik BCG Matrix highlighting pain points and fast actions to refocus portfolio, export-ready for slides.
Cash Cows
Methionine (core animal nutrition)
Methionine (core animal nutrition) is a high-share, massive-scale cash cow for Evonik, with the company holding roughly 30% of the global DL-methionine market and annual MetAMINO sales contributing a significant single-digit share of group revenues in 2024. Pricing swings occur, but vertical integration and production efficiency cushion margins and free cash flow. Capex needs remain lower than for growth segments; prioritize harvesting cash, protecting cost leadership, and avoiding overbuilding.
Coating additives (TEGO‑type portfolio)
Evonik TEGO‑type coating additives act as workhorse products entrenched with architectural and industrial customers, driving repeat volume despite a slow market growing at a low single-digit CAGR (≈2–3% in mature coatings segments in 2024). Strict specification and qualification protect volumes, while disciplined SKU management sustains solid margins; focus on service-level maintenance and higher asset utilization can extract additional EBITDA from the portfolio.
Oral care & standard precipitated silica
Toothpaste and general-purpose precipitated silica are mature, high-share franchises with stable volumes and low single-digit CAGR; global toothpaste market ~USD 29bn and precipitated silica market ~USD 5bn in 2024. Innovation is incremental and switching costs favor incumbents, yielding mid-teens margins and strong cash conversion with modest capex. Operational focus: uptime, yields, price and packaging management.
Crosslinkers and curing agents for coatings/adhesives
Crosslinkers and curing agents for epoxy, PU and related systems provide Evonik with steady, recurring orders; the global coatings market was about USD 190 billion in 2024, anchoring demand to construction and industrial cycles rather than step changes. Product know-how sustains respectable margins and pricing power. Strategy: hold share, optimize product mix and pursue targeted automation to lower COGS.
- Position: established across epoxy and PU
- Demand drivers: tied to construction/industrial cycles
- Margins: respectable due to technical know-how
- Action: hold share, optimize mix, automate processes
Hydrogen peroxide & peroxides (selected grades)
Hydrogen peroxide and selected peroxides act as cash cows: commodity-leaning but efficient plants and logistics generate steady cash; 2024 market growth remained low while differentiation rests on quality, supply reliability and application support; capex discipline is key—keep costs tight and prioritize long‑term contracts.
- Role: steady cash generation
- Edge: quality + supply reliability
- Priority: strict capex control
- Action: lock long‑term contracts
Methionine ~30%; coatings, toothpaste/silica, peroxides = steady cash
Methionine: ~30% global DL‑methionine share; MetAMINO = significant single‑digit % of group 2024 revenues. TEGO coatings: low single‑digit CAGR (~2–3%); entrenched volumes. Toothpaste/silica: global markets ~USD29bn and ~USD5bn (2024); stable mid‑teens margins. Peroxides/crosslinkers: steady cash, low growth; prioritize capex discipline and long‑term contracts.
| Product | 2024 Market | Evonik Position | Margin/Notes |
|---|---|---|---|
| Methionine | — | ~30% share | High cash, low capex |
| TEGO | Coatings ~$190bn | Established | Stable volumes |
| Toothpaste/Silica | USD29bn / USD5bn | High share | Mid‑teens margins |
| Peroxides/Crosslinkers | — | Reliable | Capex discipline |
Full Transparency, Always
Evonik Industries BCG Matrix
The file you're previewing is the final Evonik Industries BCG Matrix you'll receive after purchase — no watermarks, no placeholders, just the clean, fully formatted analysis. It maps Evonik’s business units by market share and growth, ready for immediate use in board decks or strategy sessions. After buying, the exact same document is delivered to your inbox for editing, printing, or sharing with stakeholders. No surprises, just a professional, plug-and-play report.
Dogs
Non‑differentiated commodity surfactants
Non‑differentiated commodity surfactants sit in a low‑growth segment (global surfactants growth ≈2% in 2024), driven by price‑led competition with little room to stand out. Even when volumes hold, margins erode—commodity gross margins often fall below 10% versus specialty averages. Cash is tied up in working capital with limited strategic upside; minimize exposure or carve out.
Legacy, small‑scale intermediates with no tech edge
Legacy small-scale intermediates at Evonik lack scale and unique IP, with many products treated by customers as interchangeable; in 2023 Evonik reported group sales of ~€13bn and adjusted EBITDA ~€1.7bn, highlighting limited contribution from low-margin niches. Turnarounds on these lines tend to consume cash with minimal payback. Strategic options: prune noncore SKUs, seek partnerships to scale, or exit to redeploy capital.
Over‑the‑counter grades with heavy logistics and thin spreads
Over‑the‑counter grades move long distances, generate thin spreads and seldom build strategic capability, leaving Evonik exposed to freight and energy cost swings that erode margins. These SKUs rarely defend market share in downturns, increasing risk to EBITDA contribution. Strategic response: shrink to core lanes or divest low‑margin flows to protect cash and reinvest in higher‑value specialties.
Mature region SKUs past peak relevance
Dogs:
Mature region SKUs past peak relevance
Old formulations kept for one-customer support drive demand drift and rising service costs, quietly trapping working capital and raising inventory carrying by 2024; rationalize tail SKUs, retire nonstrategic items and consolidate production to lower fixed servicing and free cash.- One-customer SKUs
- Rising service cost per SKU
- Working capital trapped
- Rationalize and simplify
Commodity contract manufacturing without IP leverage
Commodity contract manufacturing (tolling) at Evonik fills plant capacity but creates no IP moat or process learning, yielding low-single-digit economics and turning breakeven or loss when rates fall; it is nonstrategic unless explicitly structured to feed a future specialty platform.
Recommend exit or repricing with stricter ROIC/hurdle-rate gates and convert select toll flows into JV or licensed-platform deals to capture margin lift.
Cut low-growth surfactant dogs: prune, reprice or JV to protect cash and ROIC
Dogs are low‑growth, low‑margin surfactant and tolling SKUs draining cash and working capital; global surfactants growth ≈2% in 2024 and commodity GMs often <10%. These legacy one‑customer and OTC grades add service cost and inventory without IP or scale, limiting strategic upside. Recommend prune, repricing, or exit; convert select tolling to JV/license where ROIC hurdles can be met.
| Metric | Value |
|---|---|
| Segment growth | ≈2% (2024) |
| Commodity GM | <10% |
| Evonik group sales | €13bn (2023) |
Question Marks
Battery materials additives (electrolyte, binder, separator aids)
High-growth Question Mark: battery-material additives (electrolyte, binder, separator aids) sit in a market tied to EV sales (≈14.2M global EVs in 2024) and market reports estimating ~11% CAGR to 2030, but standards and supplier shares remain fluid. Technical validation and cell-level piloting typically take 12–24 months and are costly; wins at tier-1 cell makers would rapidly flip this to a Star. Invest now in pilots, co-dev, and safety/reg approvals to capture upside.
Solid‑state and silicon‑rich anode enablers
Big upside if the chemistry transition sticks: solid‑state and silicon‑rich anode markets attracted over $1 billion in venture and corporate funding by 2024, yet multiple competing chemistries and supply‑chain routes keep commercial winners uncertain. Early Evonik projects consume cash with uncertain ramp timing; landing even a few platform wins could re‑rate returns materially. Place targeted bets, not blanket coverage.
Sustainable aviation fuel catalysts and process aids
Policy tailwinds are strong—eg US 45Z SAF tax credit up to $1.25/gal—and multiple commercial SAF plants and offtake announcements emerged in 2024, making know‑how a premium for catalyst suppliers.
Market share for Evonik in SAF catalysts is embryonic and fragmented with SAF still under 1% of global jet fuel (IEA 2023), so a few lighthouse references could unlock scale.
Recommend co‑investing with select licensors and securing performance guarantees to de‑risk scale‑up and capture future share.
Biodegradable plastics modifiers & circular additives
Packaging rules tightened in 2024, pushing brands to demand performance plus verifiable end‑of‑life credentials; the global biodegradable plastics market reached about $6.8 billion in 2024 and is growing ~12% CAGR, but product share remains single‑digit for additives and modifiers while customer testing cycles and approvals are long.
- Claims verification
- LCA data provision
- Co‑branding with converters
- Long testing cycles
- Rapid market growth (2024: $6.8B)
Biotech actives for beauty and health
Fermentation‑based actives deliver proven efficacy and sustainability credentials and align with the global beauty market estimated at about $540 billion in 2024; Evonik has adjacent formulation and ingredient strengths but limited share in some biotech sub‑niches, making this a Question Mark in the BCG matrix. If scale and cost curves improve, it can convert to a Star; prioritize lighthouse SKUs and secure supply with hero brands to capture premium margins.
- 2024: global beauty ≈ $540B
- Action: build lighthouse SKUs
- Action: lock supply with hero brands
Pilots + co‑invest de‑risk batteries 14.2M EVs, SAF, bio $6.8B
Question Marks: battery additives (EVs ~14.2M in 2024; ~11% CAGR to 2030) and SAF catalysts (<1% of jet fuel; strong policy tailwinds) plus biodegradable additives ($6.8B, ~12% CAGR) and fermentation actives (beauty ~$540B) need targeted pilots, lighthouse customers and co‑invest/guarantees to de‑risk scale.
| Market | 2024 | Priority |
|---|---|---|
| Battery additives | 14.2M EVs; ~11% CAGR | Pilots, tier‑1 wins |
| SAF catalysts | <1% jet fuel | Co‑invest, offtake |
| Biodegradables | $6.8B; ~12% CAGR | Claims, LCA |
| Fermentation actives | Beauty $540B | Lighthouse SKUs |